THERAPY DOSSIER · th-658f8555aba0

Human induced pluripotent stem cell-derived OSR1+SIX2+ renal progenitor cells

Biologic · Cell therapy; no ChEMBL entity exists, so ChEMBL was not queried. ClinicalTrials.gov searched for 'induced pluripotent stem cell AND renal': 0 hits (explicit negative result). No human trial administers iPSC-derived renal progenitor cells.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Cell therapy; no ChEMBL entity exists, so ChEMBL was not queried. ClinicalTrials.gov searched for 'induced pluripotent stem cell AND renal': 0 hits (explicit negative result). No human trial administers iPSC-derived renal progenitor cells.
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26198166 ↗2015Reported benefit

Cell Therapy Using Human Induced Pluripotent Stem Cell-Derived Renal Progenitors Ameliorates Acute Kidney Injury in Mice.

MouseIschaemia-reperfusionRenalSCID (immunodeficient)MaleRenal subcapsular transplantation

Model: Acute kidney injury induced by renal ischaemia/reperfusion injury

Renal subcapsular transplantation of hiPSC-derived renal progenitors ameliorated ischaemia/reperfusion-induced acute kidney injury, significantly suppressing elevations in blood urea nitrogen and serum creatinine and attenuating histopathological changes including tubular necrosis, tubule dilatatio…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…